Analysis of patients (pts) with and without basal cell carcinoma nevus syndrome (BCCNS) in MIKIE, a randomized phase 2 study to assess the efficacy and safety of two intermittent Vismodegib (VISMO) regimens in pts with multiple Basal Cell Carcinomas (BCCs)

被引：0
|
作者：
Kunstfeld, R. [1 ]
Zloty, D. [2 ]
Tang, J. [3 ]
Basset-Seguin, N. [4 ]
Bissonnette, R. [5 ]
Grob, J. -J. [6 ]
Maher, I. [7 ]
Bergstrom, D. [8 ]
Gilberg, F. [8 ]
Dreno, B. [9 ]
Rogers, G. [10 ]
Schadendorf, D. [11 ]
机构：
[1] Med Univ Vienna, Vienna, Austria
[2] Univ British Columbia, Vancouver, BC, Canada
[3] Stanford Univ, La Jolla, CA USA
[4] Hop St Louis, Paris, France
[5] Innovaderm Res Inc, Montreal, PQ, Canada
[6] Aix Marseille Univ, Hop Timone, APHM, Marseille, France
[7] St Louis Univ, Sch Med, St Louis, MO USA
[8] Hoffman La Roche Ltd, Basel, Switzerland
[9] Univ Nantes, Nantes, France
[10] Tufts Univ, Sch Med, Boston, MA 02111 USA
[11] Univ Klinikum Essen, Essen, Germany
来源：
MELANOMA RESEARCH | 2016年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P134
引用
收藏
页码：E78 / E78
页数：1
相关论文
共 49 条
  • [41] INMUNOSUN-SOGUG trial: A prospective phase II study to assess the efficacy and safety of sunitinib as second-line (2L) treatment in patients (pts) with metastatic renal cell cancer (RCC) who received immunotherapy-based combination upfront.
    Grande, Enrique
    Alonso Gordoa, Teresa
    Reig Torras, Oscar
    Esteban, Emilio
    Castellano, Daniel
    Garcia del Muro, Xavier
    Mendez Vidal, Maria Jose
    Garcia-Donas, Jesus
    Angel Arranz, Jose
    Suarez Rodriguez, Cristina
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [42] A Phase II, Open-Label, Randomized Study to Assess the Efficacy and Safety of AZD6244 (ARRY-142886) Versus Pemetrexed in Patients with Non-small Cell Lung Cancer Who Have Failed One or Two Prior Chemotherapeutic Regimens
    Hainsworth, John D.
    Cebotaru, Cristina L.
    Kanarev, Vladimir
    Ciuleanu, Tudor E.
    Damyanov, Danail
    Stella, Phillip
    Ganchev, Hristo
    Pover, Gillian
    Morris, Clive
    Tzekova, Valentina
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (10) : 1630 - 1636
  • [43] Efficacy and Updated Safety Analysis of a Safety Run-in Cohort from Griffin, a Phase 2 Randomized Study of Daratumumab (Dara), Bortezomib (V), Lenalidomide (R), and Dexamethasone (D; Dara-Vrd) Vs. Vrd in Patients (Pts) with Newly Diagnosed (ND) Multiple Myeloma (MM) Eligible for High-Dose Therapy (HDT) and Autologous Stem Cell Transplantation (ASCT)
    Voorhees, Peter M.
    Rodriguez, Cesar
    Reeves, Brandi
    Nathwani, Nitya
    Costa, Luciano J.
    Lutska, Yana
    Hoehn, Daniela
    Pei, Huiling
    Ukropec, Jon
    Qi, Ming
    Lin, Thomas
    Richardson, Paul
    BLOOD, 2018, 132
  • [44] Phase III randomized sequential open-label study to evaluate efficacy and safety of sorafenib (SO) followed by sunitinib (SU) versus sunitinib followed by sorafenib in patients with advanced/metastatic renal cell carcinoma without prior systemic therapy (SWITCH Study) - Safety interim analysis results
    von Weikersthal, Fischer L.
    Vervenne, W. L.
    Goebell, P. J.
    Eichelberg, C.
    Freier, W.
    De Santis, M.
    Zimmermann, U.
    Bos, M. M. E. M. M.
    Trojan, L.
    Lerchenmueller, C.
    Schenck, M.
    Staehler, M.
    Floercken, A.
    Pahernik, S.
    Los, M.
    van Arkel, C.
    Schirrmacher-Memmel, S.
    Michel, M. S.
    ONKOLOGIE, 2012, 35 : 237 - 237
  • [45] Interim Safety Analysis of a Phase 2 Randomized Study of Daratumumab (Dara), Lenalidomide (R), Bortezomib (V), and Dexamethasone (d; Dara-Rvd) Vs. Rvd in Patients (Pts) with Newly Diagnosed Multiple Myeloma (MM) Eligible for High-Dose Therapy (HDT) and Autologous Stem Cell Transplantation (ASCT)
    Voorhees, Peter M.
    Costa, Luciano J.
    Reeves, Brandi
    Nathwani, Nitya
    Rodriguez, Cesar
    Lutska, Yana
    Hydutsky, Laura
    Pei, Huiling
    Ukropec, Jon
    Qi, Ming
    Linand, Thomas
    Richardson, Paul G.
    BLOOD, 2017, 130
  • [46] Randomized phase II study of first-line everolimus plus bevacizumab (E plus B) versus interferon α-2a plus bevacizumab (I plus B) in patients (pts) with metastatic renal cell carcinoma (mRCC): Record-2 final overall survival (OS) and safety results
    Ravaud, Alain
    Barrios, Carlos H.
    Alekseev, Boris Y.
    Tay, Miah Hiang
    Agarwala, Sanjiv S.
    Yalcin, Suayib
    Lin, Chia-Chi
    Shkolnik, Michail
    Matveev, Vsevolod
    Anak, Ozlem
    Gogov, Sven
    Pelov, Diana
    Louveau, Anne-Laure
    Vaury, Alexandra
    Melichar, Bohuslav
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [47] Phase III randomized sequential open-label study to evaluate efficacy and safety of sorafenib (SO) followed by sunitinib (SU) versus sunitinib followed by sorafenib in patients with advanced/metastatic renal cell carcinoma without prior systemic therapy (SWITCH Study): Safety interim analysis results.
    Michel, Maurice Stephan
    Vervenne, Walter
    Goebell, Peter J.
    Von Weikersthal, Ludwig Fischer
    Freier, Werner
    De Santis, Maria
    Zimmermann, Uwe
    Bos, Monique M. E. M.
    Trojan, Lutz
    Lerchenmuller, Christian A.
    Schenk, Marcus
    Staehler, Michael D.
    Floercken, Anne
    Pahernik, Sascha
    Los, Maartje
    Van Arkel, Cornelis
    Schirrmacher-Memmel, Silke
    Eichelberg, Christian
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [48] Trial in Progress: An Open-Label, Multi-Center Phase 2 Study to Assess the Safety and Efficacy of Burixafor (GPC-100) and Propranolol with and without G-CSF for the Mobilization of Stem Cells in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplant
    Caculitan, Nina
    Cardarelli, Josephine M.
    Khouri, Jack
    Suh, Hyung C.
    Ramanathan, Muthalagu
    Woolfrey, Ann
    BLOOD, 2023, 142
  • [49] KEVLAR: A phase 2b, multi-institutional, randomized, blinded, controlled trial to assess the safety and efficacy of two schedules of RRx-001 vs. standard of care in attenuating severe oral mucositis (SOM) in patients receiving concomitant chemoradiation (CRT) for the treatment of locally advanced squamous cell carcinomas (SCC) of the oral cavity (OC) or oropharynx (OPC)
    Reid, Tony R.
    Oronsky, Bryan
    Caroen, Scott
    Abrouk, Nacer
    Stirn, Meaghan
    Sonis, Stephen T.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345